The venture capital arm of a Taiwanese financial conglomerate with about NT$ 2 trillion (USD 31 billion) AUM is looking to invest in the biotechnology, and medical/healthcare and IT sectors. Typical equity allocations range from US$1-3 million and can be up to US$5 million. Historically the firm mainly invested in early-late stage companies in Taiwan, however currently the firm is actively seeking new investment opportunities from North America and Europe.

Within healthcare, the firm is interested in all sectors of medical technology, including both consumer and non-consumer products. The firm is agnostic to indications. The firm is less interested in therapeutics, but it would consider drug reformulation. The firm looks for products that are ready for commercialization or at the commercial stage and seeking growth/expansion capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment and advisory firm with representatives in California, Boston, and London is managing a $100 million fund focused on regenerative medicine. The firm is looking to build a portfolio of 10-12 early stage regenerative medicine companies, investing up to $10 million per deal with an initial investment of $1-3 million. The firm prefers to lead investments, though is willing to co-invest. A government agency will provide due diligence and commercialization support to the fund’s portfolio companies. The firm invests globally in regenerative medicine.

The fund focuses exclusively on regenerative medicine, including stem cells, cell therapies, immunotherapies, and tissue engineering. The firm is interested in therapeutics, and is actively looking at several immunotherapies, such as those involving T-cells, dendritic cells, and/or checkpoint inhibitors. The firm is open to any indication in the therapeutic space, as long as the underlying regenerative medicine technology is robust, and has demonstrated efficacy that is not incremental, but rather a dramatic change in the way the disease is currently treated. The firm invests in early projects, primarily from the pre-clinical stage through Phase II.

The firm is looking for compelling regenerative medicine technologies, and is prepared to build or augment the management team and/or board of a company, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based venture capital founded in 2006 has invested in nearly 50 healthcare companies in China and the U.S. across all sectors of life sciences from pharmaceuticals and medical devices to healthcare IT and diagnostics. The firm typically leads investments, though is also open to co-investing. The firm typically makes equity investments ranging from $1-$35 million, and currently has $1.7 billion in total assets under management, with their latest fund raised in 2014 at $500 million. The firm seeks to make 20-30 new investments within the next year in China and the USA.

The firm is open to all sectors and subsectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm mostly invests in 510K devices due to its faster turnaround, but will also invest in devices in the PMA pathway depending on its stage. In therapeutics, the firm is interested in all subsectors including small molecule, biologics, cell therapy, and biosimilars. The fund invests in therapeutics that are past the pre-clinical stage at Phase I to on the market, as well as medical devices that are either at the clinical stage or on the market. The firm is also interested in lab equipment and drug development enabling technologies, and is open to all indications.

The firm prefers a company with a strong management team with experience in the space. The firm will help the company fill spaces in the team if necessary, and will typically take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 1988 and headquartered in Taipei, Taiwan is currently investing from its fourth fund of US$27 million that was closed in 2013. Traditionally the firm has been focused on Taiwan-based assets but is now seeking new opportunities from North America and the EU.

Within life sciences, the firm is interested in therapeutics including small molecules, biologics, cell therapy, and gene therapy. The firm is agnostic in terms of indications. The firm prefers early stage assets that have obtained proof-of-concept data in animal models or clinical trials. The firm also considers healthcare services such as hospice and hemodialysis centers.

The firm is looking for competent management teams with sector expertise. After investment, the firm seeks to play an active role in Taiwan-based businesses or to take minority stake in overseas businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A holding company founded in 1962 and based in the Middle East invests in healthcare via an evergreen fund. The firm is a long term equity investor, and prefer to make their first investments into a company in early financing rounds. The firm’s allocations are therefore highly varied in size, from $100,000 to over $40 million throughout the life of an investment; financing is typically provided in tranches with milestone payments. The firm is generally a lead investor, and prefers to take a sizeable minority stake in a portfolio company (20% or more). The firm has the ability to invest globally but focuses on opportunities in Europe and the Middle East. The firm is highly selective regarding investment opportunities.

The firm invests across the medical device sector; the firm is open to considering the full range of device technologies and indications, including both diagnostic devices and devices with a therapeutic purpose. The firm is only interested in devices with the potential to target large markets and create new markets within healthcare; niche products are not of interest.

The firm works alongside medical device incubators, and is open to working with companies as early as the pre-prototype stage. The firm typically exits opportunities at or prior to commercialization stage, so in general market-stage companies are not of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in Sydney, Australia focuses on therapeutics and medical devices that are past pre-clinical trials. The firm currently manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Israel, and Australia. The firm does not invest in companies based in Southeast Asia.

The firm is currently looking for new investment opportunities in therapeutics and PMA medical devices. The firm is particularly interested in peripheral blood-based colorectal cancer diagnostics, but is not open to diagnostics in any other subsectors or indications. The firm is open to all subsectors and indications in therapeutics and medical devices, though is not interested in software-enabled devices or lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials with human data or on the market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Canada based venture capital firm looks to make investments of approximately $5 million with reserves left for follow on rounds. The firm looks to make one new equity or debt investment per month and gives preference to companies located in North America but is open to Australia and Western Europe depending on the opportunity. The firm does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology, software-enabled medical devices and any technology that can improve hospital operations. The firm does not have any revenue requirements for wearable technology and the firm is open to regulatory products. The firm is looking for both in-development and clinical stage devices and will consider investments in healthcare IT companies as long as the company is already established with positive cash flow.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com